E. V. Kolpachkova

E. V. Kolpachkova

Auto-generated profile, based on publicly available information

E. V. Kolpachkova

JSC "Medsi" Company Group

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2023 in Atherothrombosis
Verified
Journal Article
Open access
PDF file
ZGZ. A. Gebekova
Z. A. Gebekova
III. I. Ivanov
I. I. Ivanov
AKA. A. Kudrjavtseva
A. A. Kudrjavtseva
EKE. V. Kolpachkova
E. V. Kolpachkova
ASA. A. Sokolova
A. A. Sokolova
DND. A. Napalkov
D. A. Napalkov
Thromboembolic syndrome, the frequency of which is 8–15%, is the main danger for a patient with atrial fibrillation (AF). The left atrial appendage is the most common source of thromboembolia in atrial fibrillation. The frequency of detection of left atrial appendage thrombus in AF is 15.2% in the absence of anticoagulant therapy and 1–8% in patients using this group of drugs. The reason for the formation of thrombi in this localization during anticoagulant therapy today it is not reliably known. This article describes a clinical case of a 67-year-old patient with persistent AF and left atrial appendage thrombosis, who was hospitalized to determine further management strategies. A left atrial appendage thrombus lasted for a year despite continuous anticoagulant therapy with various oral anticoagulants at doses consistent with clinical guidelines due to the patient's absolute refusal to take warfarin, vitamin K antagonist. In addition, this article discusses the use of Thrombodynamics, a new global coagulation test, in patients with AF, which revealed a plasma hypercoagulable state with underlying persistent thrombosis in this patient on continuous oral anticoagulant treatment. The Thrombodynamics test is a promising procedure for assessing the coagulation system state and may be promising as a method for measuring the effectiveness of any oral anticoagulant. However, it is impossible to draw any definite conclusions on the basis of single observations; large clinical studies with the potential of long-term case follow-up of patients are needed.

23 April 2024 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
DND. A. Napalkov
D. A. Napalkov
ASA. A. Sokolova
A. A. Sokolova
AKA. A. Kudrjavtseva
A. A. Kudrjavtseva
ASA. I. Skripka
A. I. Skripka
AZA. V. Zhilenko
A. V. Zhilenko
DVD. K. Varvarina
D. K. Varvarina
Aim. To study the effect of dietary supplements containing omega-3 polyunsaturated fatty acids (Omega-3 PUFAs) on the parameters of ambulatory blood pressure monitoring (ABPM), 24-hour electrocardiogram (HM-ECG), and lipid profile in postmenopausal women.Material and methods. The study involved 95 postmenopausal women with a mean age of 55.9±6.0 years, without cardiovascular complications, type 2 diabetes mellitus and atrial fibrillation/flutter. The patients were divided into the main group (n=49; dietary supplement with Omega-3 PUFAs 1 g 2 times/day — content of Omega-3 PUFAs at least 30%) and the placebo group (n=46; taking capsules with vegetable oil). 17 (34.7%) patients from the main group and 18 (39.1%) patients from the placebo group took constant antihypertensive therapy, 7 (14.3%) of patients from the main group and 7 (15.2%) patients from the placebo group took constant lipid- lowering therapy. The patients did not undergo any adjustment of antihypertensive and lipid-l owering therapy during observation. The patients underwent 24-hour blood pressure and electrocardiogram monitoring, and a lipid profile evaluation at the initial visit and after 3 months.Results. It was statistically registered a significant decrease in average daily diastolic BP according to ABPM data by 1.8 mmHg. Art. (p=0.03), as well as the average daily heart rate according to HM-ECG data by 1.9 beats per minute (p=0.04) in the main group after 3 months. LDL levels tended to decrease (p=0.07) in the mail group. There were no statistically significant changes in the average daily systolic blood pressure according to ABPM, the number of supraventricular and ventricular heart rhythm disturbances, or the lipid profile (TC, LDL, triglycerides, HDL) in both groups.Conclusion. The dietary supplements containing Omega-3 PUFAs in postmenopausal women significantly reduces the level of daily diastolic blood pressure and daily heart rate without significant effect on lipid profile.

27 July 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
AKA. A. Kudriavtseva
A. A. Kudriavtseva
EKE. V. Kolpachkova
E. V. Kolpachkova
ZGZ. A. Gebekova
Z. A. Gebekova
TST. A. Sadulaeva
T. A. Sadulaeva
ASA. A. Sokolova
A. A. Sokolova
DND. A. Napalkov
D. A. Napalkov
The question of the safety of direct oral anticoagulants (DOACs), despite their high efficacy in the prevention of thrombotic events in atrial fibrillation (AF), remains relevant due to the risk of developing hemorrhagic events while taking standard doses, which requires a thorough personalized approach. The article presents a clinical case of the development of spontaneous hematomas on the skin of the upper and lower extremities and hemarthrosis of the knee joint while taking 20 mg of rivaroxaban in a 72-year-old patient with AF without impaired renal and hepatic function. Due to the increase in the residual plasma concentration of rivaroxaban, a pharmacogenetic study and the Thrombodynamics (TD) test were performed. A pharmacogenetic study did not reveal significant gene polymorphisms associated with the metabolism of rivaroxaban. However, TD allowed us to confirm the presence of significant hypocoagulation at the peak of the residual blood concentration of the drug in the blood, which could cause recurrent hemorrhagic events in the patient. In addition, the patient is taking amiodarone at a dosage of 200 mg per day, which does not allow us to rule out drug-drug interaction, despite the inconsistency of the literature data.